CSWYF OTC
China Shineway Pharmaceutical Group Limited
1W: +0.0%
1M: -6.9%
3M: -12.7%
YTD: -12.7%
1Y: -12.7%
3Y: +16.9%
5Y: +3.9%
$1.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$963M
+584.9% ▲
5Y CAGR: +71.4%
Capital Expenditures
$140M
-589.1% ▼
5Y CAGR: +60.1%
Free Cash Flow
$823M
+584.7% ▲
5Y CAGR: +73.9%
Dividends Paid
$408M
-812.6% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$251M
+139.9% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $43M | $86M | $108M | $137M | $1.1B |
| Depreciation & Amort. | $7M | $10M | $9M | $9M | $69M |
| Stock-Based Comp. | $20K | $5K | $0 | $0 | $0 |
| Change in Working Capital | $6M | $7M | $43M | -$24M | $222M |
| Other Non-Cash Items | $80M | $61M | $19M | $19M | -$473M |
| Operating Cash Flow | $102M | $120M | $179M | $141M | $963M |
| — Investing Activities — | |||||
| Capital Expenditures | -$10M | -$14M | -$19M | -$20M | -$140M |
| Acquisitions (Net) | -$16M | $14M | $521K | $0 | $983K |
| Investment Purchases | -$362M | -$57M | -$45M | -$74M | -$845M |
| Investment Sales | $368M | $59M | $46M | $75M | $528M |
| Other Investing | $6M | $2M | $546K | $3M | $184M |
| Investing Cash Flow | -$13M | $3M | -$17M | -$16M | -$272M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$29M | -$369M | -$1M | $42M | $30M |
| Stock Repurchased | -$6M | $0 | $0 | $0 | $0 |
| Dividends Paid | -$37M | -$71M | -$35M | -$45M | -$408M |
| Other Financing | $57M | $688M | -$965K | -$24M | -$15M |
| Financing Cash Flow | -$45M | -$128M | -$37M | -$27M | -$392M |
| Net Change in Cash | $82M | $11M | $66M | $105M | $251M |
| Cash End of Period | $649M | $660M | $725M | $830M | $6.1B |
| Free Cash Flow | $93M | $106M | $159M | $120M | $823M |